Paris, France - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN, Geneva, Switzerland) presented new data from its Phase IIa trial of ADX10059 to treat gastroesophageal reflux disease (GERD) today at the United European Gastroenterology Week (www.uegw.org) conference in Paris, France. GERD is a common disorder, affecting about 15% of the population. New data released today for the first time show that ADX10059 controlled stomach acid reflux during the critical period following meals, when GERD can be most troublesome. Top-line data, first released in April, showed that the product controlled acid reflux over a 24 hour period.
